Physician profile
Iris M Greeson
NPI 1487960258
$915.31
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $443 · 2022: $291 · 2023: $181.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $181.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $181.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $203.10 | 2021-2023 | |
| Abbott Laboratories | $130.40 | 2021-2023 | Freestyle Libre 3 |
| Janssen Pharmaceuticals, INC | $121.50 | 2022 | |
| Grifols USA, LLC | $100.00 | 2022 | |
| Dexcom, INC. | $69.29 | 2021 | |
| Lilly USA, LLC | $42.28 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $41.64 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $41.38 | 2021 | |
| Radius Health, INC. | $39.67 | 2021 | |
| Amgen INC. | $29.48 | 2021 | |
| Esperion Therapeutics, INC. | $18.96 | 2021 | |
| Merck Sharp & Dohme LLC | $17.24 | 2021 | |
| Novo Nordisk INC | $16.97 | 2021 | |
| Glaxosmithkline, LLC. | $15.98 | 2023 | Bexsero |
| Insulet Corporation | $15.11 | 2021 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $12.31 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Iris Greeson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.